Table 2.
Two-way tabulation (%) of allopurinol use by flares in participants with gout
| Allopurinol | Number of gout flares in the preceding year (%)1 | Total | ||
|---|---|---|---|---|
| None | 1 | ≥ 2 | ||
| Never used | 22.1 (16.3, 29.2) | 10.0 (6.1, 15.9) | 7.6 (4.1, 13.6) | 39.7 (31.8, 48.2) |
| Prior use | 14.5 (9.4, 21.8) | 4.2 (1.8, 9.4) | 4.5 (2.3, 8.6) | 23.2 (16.9, 21.0) |
| Current use | 21.6 (15.7, 28.9) | 3.0 (1.3, 6.6) | 12.5 (7.9, 19.2) | 37.1 (29.6, 45.3) |
| Total | 58.2 (50.3, 65.8) | 17.2 (11.8, 24.3) | 24.6 (18.3, 32.2) | 100 |
1Percentages are absolute percentages of the entire gout subpopulation, and numbers in brackets are 95% confidence intervals